Hvivo (HVO) RNS Announcements

Add to Alert list
Date Time Source Announcement
14 Dec 2020 07:00 AM
RNS
MHRA approval for nasal COVID-19 vaccine trial
07 Dec 2020 07:00 AM
RNS
Venn Life Sciences contract wins
24 Nov 2020 07:00 AM
RNS
Directors Change
19 Nov 2020 07:00 AM
RNS
Collaboration with HIC-VAC and Wellcome Trust
05 Nov 2020 07:00 AM
RNS
New £2.5m Influenza Challenge Study Contract Win
30 Oct 2020 11:00 AM
RNS
Price Monitoring Extension
30 Oct 2020 07:10 AM
RNS
Exercise of Share Options
30 Oct 2020 07:00 AM
RNS
New 2-year contract with a tier 1 German company
20 Oct 2020 07:00 AM
RNS
Contract Signed with UK Government
16 Oct 2020 08:47 AM
RNS
Statement re further media comment
30 Sep 2020 07:00 AM
RNS
Interim Results for 6 months ended 30 June 2020
28 Sep 2020 07:00 AM
RNS
New £4.3m Challenge Study Contract Win
24 Sep 2020 07:00 AM
RNS
Statement re price movement and press speculation
23 Sep 2020 04:41 PM
RNS
Second Price Monitoring Extn
23 Sep 2020 04:36 PM
RNS
Price Monitoring Extension
22 Sep 2020 07:30 AM
RNS
Exercise of Investor Warrants and Issue of Shares
22 Sep 2020 07:00 AM
RNS
New Contract Win
07 Sep 2020 07:00 AM
RNS
hVIVO present at 2020 ERS International Congress
10 Aug 2020 07:00 AM
RNS
Major New Contract Win with Top 3 Pharma Company
04 Aug 2020 07:00 AM
RNS
New Contract Win with Carna Bioscience ("Carna")
28 Jul 2020 07:00 AM
RNS
Contract for COVID-19 Vaccine Trial
22 Jul 2020 12:43 PM
RNS
Result of AGM
15 Jul 2020 07:00 AM
RNS
Option to Acquire CHIMagents Limited
08 Jul 2020 07:00 AM
RNS
Upcoming Investor Events
07 Jul 2020 07:10 AM
RNS
Exercise of Warrants
07 Jul 2020 07:00 AM
RNS
Additional Laboratory Services Contracts Signed
26 Jun 2020 01:05 PM
RNS
Notice of AGM
24 Jun 2020 07:00 AM
RNS
Results for the year ended 31 December 2019
17 Jun 2020 09:32 AM
EQS
Open Orphan presenting at virtual Investor Foru...
15 Jun 2020 07:00 AM
RNS
Positive Phase I results published in The Lancet
11 Jun 2020 12:15 PM
RNS
Result of General Meeting
11 Jun 2020 07:00 AM
RNS
Major New Contract Signed
10 Jun 2020 05:40 PM
RNS
Holding(s) in Company
10 Jun 2020 05:35 PM
RNS
Holding(s) in Company
10 Jun 2020 05:30 PM
RNS
Holding(s) in Company
04 Jun 2020 07:00 AM
RNS
Launch of Covid-19 Antibody Testing
22 May 2020 10:53 AM
RNS
Results of Fundraising
22 May 2020 07:01 AM
RNS
PrimaryBid.com Offer
22 May 2020 07:00 AM
RNS
Proposed Fundraising to raise up to £12 million
18 May 2020 09:05 AM
RNS
Second Price Monitoring Extn
18 May 2020 09:00 AM
RNS
Price Monitoring Extension
18 May 2020 07:00 AM
RNS
Update on antibody test and share price movement
11 May 2020 07:00 AM
RNS
Appointment of Joint Broker
11 May 2020 07:00 AM
RNS
New COVID-19 Antibody Testing Partnership
04 May 2020 07:00 AM
RNS
Major New Contract and Directorate Change
23 Apr 2020 07:00 AM
RNS
Testing of anti-viral for treating COVID-19
14 Apr 2020 02:06 PM
RNS
Second Price Monitoring Extn
14 Apr 2020 02:01 PM
RNS
Price Monitoring Extension
23 Mar 2020 04:43 PM
RNS
Second Price Monitoring Extn
23 Mar 2020 04:37 PM
RNS
Price Monitoring Extension

hVIVO is a contract research organization that conducts human challenge clinical trials for respiratory and infectious disease vaccines and therapeutics:

hVIVO offers services such as challenge trials, assay development, field trial bio-logistics, cell based assays, molecular services, compound efficacy and VRM, and biomarker analysis.

Formerly known as Retroscreen, hVIVO was renamed in 2015 when it went public on the London Stock Exchange.

hVIVO has a portfolio of 11 human challenge models, with more models in development. Their portfolio includes models for influenza, respiratory syncytial virus, human rhinovirus, asthma, COPD, cough, malaria, COVID-19, and hMPV.

hVIVO share price launched at 33p in 2012.

UK 100

Latest directors dealings